Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Castle Biosciences, Inc. is a molecular diagnostics company focused on developing and commercializing genomic and clinicopathologic tests that inform treatment decisions for patients with cancer and other complex diseases. The company operates within the precision medicine and diagnostic testing industries, with an emphasis on providing actionable risk stratification and prognostic information to physicians. Its tests are designed to guide clinical decision-making, particularly in oncology and dermatology, by identifying disease aggressiveness and likelihood of progression.
Founded in 2008, Castle Biosciences initially focused on prognostic testing for melanoma and gradually expanded its portfolio through internal development and acquisitions. The company completed its initial public offering in 2020 and is listed on the NASDAQ under the ticker CSTL. Over time, it has evolved into a multi-product diagnostics platform serving dermatologists, oncologists, gastroenterologists, and other specialists across the United States.
Business Operations
Castle Biosciences generates revenue primarily through the sale of proprietary diagnostic tests performed in its own laboratories. Its core business segments include DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, DecisionDx-CMSeq, myPath Melanoma, IDgenetix, and TissueCypher. These tests assess gene expression or molecular markers to predict disease behavior, recurrence risk, or treatment response, and are reimbursed through a mix of private insurance, Medicare, and patient self-pay arrangements.
Operations are primarily domestic, with testing services performed in company-controlled laboratories located in the United States. The company controls its assay technologies, bioinformatics pipelines, and laboratory infrastructure, allowing it to maintain quality control and protect intellectual property. Key subsidiaries include Castle Biosciences Reference Laboratories and AltheaDx, Inc., which support laboratory operations and pharmacogenomic testing services.
Strategic Position & Investments
Castle Biosciences’ strategy centers on expanding its test menu, increasing clinical adoption, and securing broader reimbursement coverage. Growth initiatives include continued clinical validation studies, guideline inclusion efforts, and expansion into adjacent disease categories where molecular risk stratification can improve outcomes. The company emphasizes evidence generation through peer-reviewed publications and real-world data to support payer coverage and physician adoption.
Strategic investments have included the acquisition of AltheaDx, Inc. to enter pharmacogenomics and the acquisition of Cernostics, Inc., which added the TissueCypher test for Barrett’s esophagus risk assessment. These acquisitions broadened the company’s reach beyond dermatologic oncology into gastroenterology and personalized medicine. Castle Biosciences continues to invest in emerging molecular diagnostics technologies and data analytics to enhance test performance and clinical utility.
Geographic Footprint
Castle Biosciences is headquartered in Friendswood, Texas, and its operations are primarily concentrated in the United States. The company serves physicians and healthcare systems across all major U.S. regions, with a national commercial sales organization supporting test adoption in dermatology, oncology, and gastroenterology practices.
While the company does not maintain significant laboratory operations outside the United States, its tests may be ordered for patients internationally on a limited basis through U.S.-based providers. Overall, its geographic footprint and revenue base remain predominantly domestic, with strategic focus on deepening penetration in the U.S. healthcare market.
Leadership & Governance
Castle Biosciences is led by an executive team with backgrounds in molecular diagnostics, life sciences, and healthcare commercialization. The leadership emphasizes evidence-based medicine, disciplined growth, and long-term value creation through clinically meaningful innovation. Corporate governance follows U.S. public company standards, with oversight provided by an independent board of directors.
Key executives include:
- Derek J. Maetzold – President and Chief Executive Officer
- Brett J. Kline – Chief Financial Officer
- John P. Lapis – Chief Operating Officer
- William D. Gunn – Chief Medical Officer
- Anthony J. Comstock – Chief Commercial Officer